Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 270 entries
View as:

A Safety and Efficacy Study of Tralokinumab in Adults With Asthma

Phase: N/A Priority: Normal
NCT ID: NCT01402986 Org: User:
Start: 08/31/11 End: 02/28/14 Due: 02/28/15

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02117219 Org: User:
Start: 05/20/14 End: 04/30/19 Due: 04/30/20

A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT01283139 Org: User:
Start: 03/31/11 End: 04/17/14 Due: 04/17/15

A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00983619 Org: User:
Start: 04/16/10 End: 03/21/19 Due: 03/21/20

A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.

Phase: N/A Priority: Normal
NCT ID: NCT04019561 Org: User:
Start: 09/23/19 End: 05/06/21 Due: 05/06/22

Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers

Phase: N/A Priority: Normal
NCT ID: NCT00192283 Org: User:
Start: 09/30/00 End: 05/31/02 Due: 05/31/03

A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01268059 Org: User:
Start: 12/16/10 End: 09/11/13 Due: 09/11/14

A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01712399 Org: User:
Start: 01/28/13 End: 12/30/15 Due: 12/30/16

A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT02524782 Org: User:
Start: 10/07/15 End: 04/14/17 Due: 04/14/18

BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00074048 Org: User:
Start: 10/31/03 End: 07/31/08 Due: 07/31/09

Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)

Phase: N/A Priority: Normal
NCT ID: NCT00233064 Org: User:
Start: 10/31/05 End: 11/30/07 Due: 11/30/08

A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02334306 Org: User:
Start: 06/08/15 End: 08/13/18 Due: 08/13/19

Safety Study to Evaluate FluMist in Immunocompromised Children

Phase: N/A Priority: Normal
NCT ID: NCT00112112 Org: User:
Start: 08/01/05 End: 05/01/08 Due: 05/01/09

A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT00482989 Org: User:
Start: 06/30/07 End: 09/30/10 Due: 09/30/11

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older

Phase: N/A Priority: Normal
NCT ID: NCT00192153 Org: User:
Start: 07/31/01 End: 10/31/01 Due: 10/31/02

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT00192192 Org: User:
Start: 11/30/00 End: 12/31/00 Due: 12/31/01

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT03822351 Org: User:
Start: 12/19/18 End: 07/18/23 Due: 07/18/24

A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT01268566 Org: User:
Start: 01/31/11 End: 11/30/12 Due: 11/30/13

A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma

Phase: N/A Priority: Normal
NCT ID: NCT00659659 Org: User:
Start: 01/31/08 End: 03/31/11 Due: 03/31/12

Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.

Phase: N/A Priority: Normal
NCT ID: NCT00192400 Org: User:
Start: 03/31/02 End: 11/30/02 Due: 11/30/03

Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive

Phase: N/A Priority: Normal
NCT ID: NCT00263744 Org: User:
Start: 11/30/99 End: 06/30/01 Due: 06/30/02

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03811652 Org: User:
Start: 12/20/18 End: 12/10/19 Due: 12/10/20

A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children

Phase: N/A Priority: Normal
NCT ID: NCT00626808 Org: User:
Start: 10/31/07 End: 03/31/10 Due: 03/31/11

A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).

Phase: N/A Priority: Normal
NCT ID: NCT00768079 Org: User:
Start: 02/02/09 End: 03/10/11 Due: 03/10/12

Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00796055 Org: User:
Start: 08/31/09 End: 06/30/10 Due: 06/30/11